Free shipping on all orders over $ 500

AMG 337

Cat. No. M5310

All AbMole products are for research use only, cannot be used for human consumption.

AMG 337 Structure
Size Price Availability Quantity
5mg USD 95  USD95 In stock
10mg USD 160  USD160 In stock
25mg USD 270  USD270 In stock
50mg USD 480  USD480 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: AMG 337 potently inhibits the enzymatic activity of WT MET and a subset of MET mutants found in papillary renal cell carcinoma. The inability of AMG 337 to inhibit the Y1230 and D1228 mutants is likely the result of a disruption of the inactive confirmation of the activation loop in the MET kinase domain. AMG 337 also inhibits cell based HGF-induced MET phosphorylation in PC3 cells with IC50 of 5nM. AMG 337 inhibits proliferation in MET-dependent cancer cell lines. AMG 337 inhibits signaling through the PI3K and MAPK pathways in MET-amplified gastric cancer cell lines resulting in profound effects on cell proliferation and survival. In vivo: AMG 337 exhibits impressive potency with >90% inhibition of Gab-1 phosphorylation at a dose of 0.75 mg/kg (32 nmol/L free-drug concentration). AMG 337 is well tolerated at continuously administered doses that corresponded with complete MET inhibition for 24 hours, suggesting that AMG 337 has the preclinical attributes required to test the role of MET in human cancer.

Chemical Information
Molecular Weight 463.46
Formula C23H22FN7O3
CAS Number 1173699-31-4
Solubility (25°C) 95 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Hughes PE, et al. Mol Cancer Ther. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.

[2] Du Z, et al. Mol Cancer Ther. Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma.

Related c-Met Products
Zurletrectinib

Zurletrectinib (ICP-723) is a potent tyrosine kinase inhibitor. Zurletrectinib serves as an antineoplastic agent. Zurletrectinib can used for research of TRK-mediated related diseases.

ABN401 

ABN401 is a highly potent and selective ATP-competitive c-MET inhibitor with an IC50 value of 10 nM.

(Z)-Semaxanib

(Z)-Semaxanib is a potent tyrosine kinase inhibitor.

MET kinase-IN-2 

MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM.

BMS-817378

BMS-817378 is a potent and selective inhibitor of MET with IC50 of 1.7 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: AMG 337 supplier, c-Met, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.